Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Windtree TherapeuticsWINT +100.00% Quick Ratio is 0.33 as of Sep. 2025, which is 75% below its 10-year median of 1.30. The stock has 2 warning signs investors should review. Among 1,411 Biotechnology companies, Windtree Therapeutics ranks worse than 92.63% on this metric.
Windtree Therapeutics (OTCPK:WINT) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Windtree Therapeutics Quick Ratio Related Terms
Windtree Therapeutics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Windtree Therapeutics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Windtree Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Windtree Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Windtree Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Windtree Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Windtree Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Windtree Therapeutics (WINT) has a Quick Ratio of 0.33 as of Sep. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Windtree Therapeutics and its competitors. This is 75% below median its historical median of 1.30. Over the past decade, Windtree Therapeutics' Quick Ratio has ranged from 0.06 to 6.58. According to the industry distribution chart, Windtree Therapeutics ranks #1307 out of 1411 companies in the Biotechnology industry, placing it in the top 92.6%.
Is Windtree Therapeutics' Quick Ratio too high?
Windtree Therapeutics' current Quick Ratio of 0.33 is 75% below median its 10-year median of 1.30. Over the past 10 years, this metric has ranged from a low of 0.06 to a high of 6.58. The Biotechnology industry median Quick Ratio is 3.57. Windtree Therapeutics' value of 0.33 is 90.8% below this industry median. Based on the distribution chart, Windtree Therapeutics ranks #1307 out of 1411 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Windtree Therapeutics' Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Windtree Therapeutics ranks #1307 out of 1411 companies for Quick Ratio. This places Windtree Therapeutics in the lower half of its industry. The industry median Quick Ratio is 3.57. Windtree Therapeutics' value of 0.33 is 90.8% below this benchmark. Historically, Windtree Therapeutics' own Quick Ratio has ranged from 0.06 to 6.58 over the past decade. While the company's 10-year median is 1.30 vs. the industry median of 3.57, Windtree Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.57, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Windtree Therapeutics's current Quick Ratio of 0.33 is 90.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Windtree Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Windtree Therapeutics's current Quick Ratio is 0.33, which is 75% below median its own 10-year median of 1.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windtree Therapeutics stock overvalued right now?
Windtree Therapeutics (WINT) has a current Quick Ratio of 0.33. The current Quick Ratio is 0.33, which is 75% below median its 10-year median of 1.30 and 90.8% below the Biotechnology industry median of 3.57. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Windtree Therapeutics (WINT), the current Quick Ratio is 0.33 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WINT has been successfully added to your 
